Impact of Tocilizumab on endothelial function following Out-of-Hospital Cardiac Arrest: A Substudy of the IMICA randomized controlled Trial
Plasma syndecan-1 decline was less pronounced in comatose OHCA patients treated with tocilizumab, without affecting sTM or PECAM-1. This contrasts previous IMICA findings of reduced systemic inflammation, vasopressor use, and myocardial injury, suggesting a complex relationship between inflammation and endothelial injury.Finally, PECAM-1 levels already at hospital admission had a moderate predictive value for mortality.
Authors
- Pär I. Johansson (ORCID: https://orcid.org/0000-0001-9778-5964)
- Zakaria Alaoui-Ismaili (ORCID: https://orcid.org/0009-0007-8792-2452)
- Martin Frydland (ORCID: https://orcid.org/0000-0003-1543-8948)
- A Meyer
- Laust E. R. Obling
- Martin A. S. Meyer
- Johannes Grand
- Sebastian Wiberg
- Jesper Kjaergaard
- Yassin Alaoui-Ismaili
- Christian Hassager
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- IT University of Copenhagen (DK)
Publication Details
- Journal
- European Heart Journal Acute Cardiovascular Care
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1093/ehjacc/zuag034
- Primary Topic
- Cardiac and Coronary Surgery Techniques
- Type
- article
- Field-Weighted Citation Impact
- 0.00